cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24297121
title: Supplementary Material for: Age-dependent Effects of Transgenic 2D2 Mice Used to Induce Passive EAE in C57BL/6 Mice

description: Introduction: Multiple sclerosis (MS) is a neurodegenerative autoimmune disease which worsens with age. Here we examined the influence of age on passive experimental autoimmune encephalomyelitis (P-EAE), a model to study MS, using young and mature adult 2D2 transgenic donor mice to induce pathology in WT C57BL6/J mice. Methods: Lymphocytes from young adult (i.e., 10-week-old) or mature adult (i.e., 6-month-old) transgenic donor mice were characterized by flow cytometry prior to injection of cultured leukocytes into adult female WT recipient mice, with a special focus on transgenic T cell phenotypes. Results: Our findings show age-dependent changes in memory T cell phenotypes correlated with more severe clinical and histological disease when donor cells originated from young as compared to mature adult mice. Conclusion: Not only do these results demonstrate that the age of the 2D2 transgenic donor mice is critical in establishing P-EAE, but the differential effects might also identify age-dependent factors that contribute to EAE and perhaps MS.
DOI: 10.6084/m9.figshare.24297121.v1
title: Supplementary Material for: Age-dependent Effects of Transgenic 2D2 Mice Used to Induce Passive EAE in C57BL/6 Mice

description: Introduction: Multiple sclerosis (MS) is a neurodegenerative autoimmune disease which worsens with age. Here we examined the influence of age on passive experimental autoimmune encephalomyelitis (P-EAE), a model to study MS, using young and mature adult 2D2 transgenic donor mice to induce pathology in WT C57BL6/J mice. Methods: Lymphocytes from young adult (i.e., 10-week-old) or mature adult (i.e., 6-month-old) transgenic donor mice were characterized by flow cytometry prior to injection of cultured leukocytes into adult female WT recipient mice, with a special focus on transgenic T cell phenotypes. Results: Our findings show age-dependent changes in memory T cell phenotypes correlated with more severe clinical and histological disease when donor cells originated from young as compared to mature adult mice. Conclusion: Not only do these results demonstrate that the age of the 2D2 transgenic donor mice is critical in establishing P-EAE, but the differential effects might also identify age-dependent factors that contribute to EAE and perhaps MS.
DOI: 10.6084/m9.figshare.24265159
title: Supplementary Material for: Fetal anemia: Determinants and perinatal outcomes according to the method of intrauterine blood transfusion

description: Introduction: Fetal anemia from hemolytic disease treated by intrauterine transfusion (IUT) can be performed by intraperitoneal, intracardiac and intravascular transfusion (IVT). Objective of our study was to compare different transfusion techniques. Methods: Retrospective review of IUT secondary to red cell alloimmunization at eight international centers from 2012-2020. Severe anemia suspected if middle cerebral artery peak systolic velocity  1.5 MoM. Demographic, delivery and postnatal variables were analyzed. Results: Total of 344 procedures, 325 IVT and 19 other techniques (non-IVT) included. No difference in demographics, history of stillbirth (20.5 vs 15.8%, p=0.7), prior pregnancy IUT (25.6 vs 31.6%, p=0.5) or neonatal transfusion (36.1 vs 43.8%, p=0.5). At first IUT, non-IVT had higher hydrops (42.1% vs. 20.4%, p=0.03), lower starting hematocrit (13.3% (±6) vs. 17.7% (±8.2), p = 0.04) and trend towards lower gestational age (24.6 (20.1-27) vs. 26.4 (23.2-29.6) weeks, p=0.08). No difference in birthweight, neonatal phototherapy, exchange or simple transfusion. Conclusion: This is one of the largest studies comparing techniques to treat fetal anemia. IVT was most performed, other techniques were more likely performed in hydrops and lower starting hematocrit was seen. Neither technique affected outcomes. This study may suggest that physician’s experience may be the strongest contributor of outcomes.
DOI: 10.6084/m9.figshare.24265159.v1
title: Supplementary Material for: Fetal anemia: Determinants and perinatal outcomes according to the method of intrauterine blood transfusion

description: Introduction: Fetal anemia from hemolytic disease treated by intrauterine transfusion (IUT) can be performed by intraperitoneal, intracardiac and intravascular transfusion (IVT). Objective of our study was to compare different transfusion techniques. Methods: Retrospective review of IUT secondary to red cell alloimmunization at eight international centers from 2012-2020. Severe anemia suspected if middle cerebral artery peak systolic velocity  1.5 MoM. Demographic, delivery and postnatal variables were analyzed. Results: Total of 344 procedures, 325 IVT and 19 other techniques (non-IVT) included. No difference in demographics, history of stillbirth (20.5 vs 15.8%, p=0.7), prior pregnancy IUT (25.6 vs 31.6%, p=0.5) or neonatal transfusion (36.1 vs 43.8%, p=0.5). At first IUT, non-IVT had higher hydrops (42.1% vs. 20.4%, p=0.03), lower starting hematocrit (13.3% (±6) vs. 17.7% (±8.2), p = 0.04) and trend towards lower gestational age (24.6 (20.1-27) vs. 26.4 (23.2-29.6) weeks, p=0.08). No difference in birthweight, neonatal phototherapy, exchange or simple transfusion. Conclusion: This is one of the largest studies comparing techniques to treat fetal anemia. IVT was most performed, other techniques were more likely performed in hydrops and lower starting hematocrit was seen. Neither technique affected outcomes. This study may suggest that physician’s experience may be the strongest contributor of outcomes.
DOI: 10.2908/rail_eq_wagon
title: Wagons and their load capacity by type of wagons
title: Wagons et leur capacité, par type de wagon
title: Güterwagen und ihre Tragfährigkeit, nach Kategorie der Güterwagen
DOI: 10.6084/m9.figshare.24224104
title: Supplementary Material for: PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

description: Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib could demonstrate superior efficacy. Methods This random phase III open-label study evaluated the sequential treatment with pexa-vec followed by sorafenib compared to sorafenib in patients with advanced HCC and no prior systemic treatment. The primary endpoint is overall survival (OS). Key secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR). Safety was assessed in all patients who received ≥ 1 dose of study treatment. Results The study was conducted at 142 sites in 16 countries. From December 30, 2015, to the interim analysis on August 2, 2019, 459 patients were randomly assigned (pexa-vec plus sorafenib 234, sorafenib: 225). At the interim analysis the median OS was 12.7 months (95% CI: 9.89, 14.95) in the pexa-vec plus sorafenib arm and 14.0 months (95% CI: 11.01, 18.00) in the sorafenib arm. This led to early termination of the study. The median TTP was 2.0 months (95% CI: 1.77, 2.96) and 4.2 months (95% CI: 2.92, 4.63); ORR was 19.2% (45 patients) and 20.9% (47 patients); and DCR was 50.0% (117 patients) and 57.3% (129 patients) in the pexa-vec plus sorafenib and sorafenib arms, respectively. Serious adverse events were reported in 117 (53.7%) patients in the pexa-vec plus sorafenib and 77 (35.5%) patients in the sorafenib arm. Liver failure was the most frequently reported in both groups. Discussion/Conclusion Sequential pexa-vec plus sorafenib treatment did not demonstrate increased clinical benefit in advanced HCC and fared worse compared to sorafenib alone. The advent of the added value of checkpoint inhibitors should direct any further development of oncolytic virus therapy strategies.
DOI: 10.6084/m9.figshare.24224104.v1
title: Supplementary Material for: PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

description: Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib could demonstrate superior efficacy. Methods This random phase III open-label study evaluated the sequential treatment with pexa-vec followed by sorafenib compared to sorafenib in patients with advanced HCC and no prior systemic treatment. The primary endpoint is overall survival (OS). Key secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR). Safety was assessed in all patients who received ≥ 1 dose of study treatment. Results The study was conducted at 142 sites in 16 countries. From December 30, 2015, to the interim analysis on August 2, 2019, 459 patients were randomly assigned (pexa-vec plus sorafenib 234, sorafenib: 225). At the interim analysis the median OS was 12.7 months (95% CI: 9.89, 14.95) in the pexa-vec plus sorafenib arm and 14.0 months (95% CI: 11.01, 18.00) in the sorafenib arm. This led to early termination of the study. The median TTP was 2.0 months (95% CI: 1.77, 2.96) and 4.2 months (95% CI: 2.92, 4.63); ORR was 19.2% (45 patients) and 20.9% (47 patients); and DCR was 50.0% (117 patients) and 57.3% (129 patients) in the pexa-vec plus sorafenib and sorafenib arms, respectively. Serious adverse events were reported in 117 (53.7%) patients in the pexa-vec plus sorafenib and 77 (35.5%) patients in the sorafenib arm. Liver failure was the most frequently reported in both groups. Discussion/Conclusion Sequential pexa-vec plus sorafenib treatment did not demonstrate increased clinical benefit in advanced HCC and fared worse compared to sorafenib alone. The advent of the added value of checkpoint inhibitors should direct any further development of oncolytic virus therapy strategies.
DOI: 10.6084/m9.figshare.24240598
title: Supplementary Material for: Regional variation in the use of percutaneous kidney biopsy in Japan

description: Introduction: The regional variation in the use of percutaneous kidney biopsy in Japan remains unknown. There are several large datasets of kidney biopsies in Japan, but an exhaustive survey of kidney biopsies is lacking. Methods: We analyzed insurance claims for percutaneous kidney biopsies registered in the National Database of Health Insurance Claims and Specific Health Checkups of Japan, which is the closest to a complete dataset of kidney biopsies performed in Japan. In combination with other nationwide survey results, the number of inpatient percutaneous kidney biopsies per population in each prefecture was calculated. Factors associated with the frequency of percutaneous kidney biopsies were also explored. Results: The database contained 22,419 health insurance claims for percutaneous kidney biopsy in the fiscal year 2020. The frequency of inpatient percutaneous kidney biopsies could be up to 4.8 times as frequent in one prefecture than in another, even after adjusting for age and sex. The frequency of inpatient percutaneous kidney biopsies showed a positive correlation with the number of annual kidney transplants and patients on peritoneal dialysis per population and a weak negative correlation with the prevalence of reduced kidney function in the population aged 40–74 years. Conclusion: We found a large regional variation in the frequency of inpatient percutaneous kidney biopsies. Kidney transplants and peritoneal dialysis might be offered more frequently in regions with a higher frequency of kidney biopsy. This is the first dataset that shows more than 20,000 kidney biopsies were performed per year in Japan, as of 2020.
DOI: 10.6084/m9.figshare.24240598.v1
title: Supplementary Material for: Regional variation in the use of percutaneous kidney biopsy in Japan

description: Introduction: The regional variation in the use of percutaneous kidney biopsy in Japan remains unknown. There are several large datasets of kidney biopsies in Japan, but an exhaustive survey of kidney biopsies is lacking. Methods: We analyzed insurance claims for percutaneous kidney biopsies registered in the National Database of Health Insurance Claims and Specific Health Checkups of Japan, which is the closest to a complete dataset of kidney biopsies performed in Japan. In combination with other nationwide survey results, the number of inpatient percutaneous kidney biopsies per population in each prefecture was calculated. Factors associated with the frequency of percutaneous kidney biopsies were also explored. Results: The database contained 22,419 health insurance claims for percutaneous kidney biopsy in the fiscal year 2020. The frequency of inpatient percutaneous kidney biopsies could be up to 4.8 times as frequent in one prefecture than in another, even after adjusting for age and sex. The frequency of inpatient percutaneous kidney biopsies showed a positive correlation with the number of annual kidney transplants and patients on peritoneal dialysis per population and a weak negative correlation with the prevalence of reduced kidney function in the population aged 40–74 years. Conclusion: We found a large regional variation in the frequency of inpatient percutaneous kidney biopsies. Kidney transplants and peritoneal dialysis might be offered more frequently in regions with a higher frequency of kidney biopsy. This is the first dataset that shows more than 20,000 kidney biopsies were performed per year in Japan, as of 2020.
DOI: 10.6084/m9.figshare.24320620
title: Supplementary Material for: Inhibition of estradiol signaling in the basolateral amygdala impairs extinction memory recall for heroin-conditioned cues in a sex-specific manner

description: Relapse is a major treatment barrier for opioid use disorder (OUD). Environmental cues become associated with the rewarding effects of opioids and can precipitate relapse, even after numerous unreinforced cue presentations, due to deficits in extinction memory recall (EMR). Estradiol (E2) modulates EMR of fear-related cues, but it is unknown whether E2 impacts EMR of reward cues and what brain region(s) are responsible for E2’s effects. Here, we hypothesize that inhibition of E2 signaling in the basolateral amygdala (BLA) will impair EMR of a heroin-associated cue in both male and female rats. We pharmacologically manipulated E2 signaling to characterize the role of E2 in the BLA on heroin cue EMR. Following heroin self-administration, during which a light/tone cue was co-presented with each heroin infusion, rats underwent cued extinction to extinguish the conditioned association between the light/tone and heroin. During extinction, E2 signaling in the BLA was blocked by an aromatase inhibitor or specific estrogen receptor (ER) antagonists. The next day, subjects underwent a cued test to assess heroin cue EMR. In both experiments, females took more heroin than males (mg/kg) and had higher operant responding during cued extinction. Inhibition of E2 synthesis in the BLA impaired heroin cue EMR in both sexes. Notably, E2’s actions are mediated by different ER mechanisms, ERα in males but ERβ in females. This study is the first to demonstrate a behavioral role for centrally-produced E2 in the BLA and that E2 also impacts EMR of reward-associated stimuli in both sexes.
DOI: 10.6084/m9.figshare.24320620.v1
title: Supplementary Material for: Inhibition of estradiol signaling in the basolateral amygdala impairs extinction memory recall for heroin-conditioned cues in a sex-specific manner

description: Relapse is a major treatment barrier for opioid use disorder (OUD). Environmental cues become associated with the rewarding effects of opioids and can precipitate relapse, even after numerous unreinforced cue presentations, due to deficits in extinction memory recall (EMR). Estradiol (E2) modulates EMR of fear-related cues, but it is unknown whether E2 impacts EMR of reward cues and what brain region(s) are responsible for E2’s effects. Here, we hypothesize that inhibition of E2 signaling in the basolateral amygdala (BLA) will impair EMR of a heroin-associated cue in both male and female rats. We pharmacologically manipulated E2 signaling to characterize the role of E2 in the BLA on heroin cue EMR. Following heroin self-administration, during which a light/tone cue was co-presented with each heroin infusion, rats underwent cued extinction to extinguish the conditioned association between the light/tone and heroin. During extinction, E2 signaling in the BLA was blocked by an aromatase inhibitor or specific estrogen receptor (ER) antagonists. The next day, subjects underwent a cued test to assess heroin cue EMR. In both experiments, females took more heroin than males (mg/kg) and had higher operant responding during cued extinction. Inhibition of E2 synthesis in the BLA impaired heroin cue EMR in both sexes. Notably, E2’s actions are mediated by different ER mechanisms, ERα in males but ERβ in females. This study is the first to demonstrate a behavioral role for centrally-produced E2 in the BLA and that E2 also impacts EMR of reward-associated stimuli in both sexes.
DOI: 10.6084/m9.figshare.24486523
title: Supplementary Material for: Short-term versus long-term mentalization-based therapy for borderline personality disorder: a randomized clinical trial (MBT-RCT)

description: Introduction Borderline personality disorder (BPD) is a prevalent psychiatric disorder. Mentalization-based therapy (MBT) is an evidence-based intervention, and several countries offer long-term treatments for BPD, which is resource demanding. No previous trial has compared short-term with long-term MBT. Objective To assess the efficacy and safety of short-term versus long-term MBT for outpatients with BPD. Methods Adult outpatients (≥18 years) with subthreshold or diagnosed BPD were randomly assigned (1:1) to short-term MBT (5 months) or long-term MBT (14 months) using a web-based system. The primary outcome was BPD symptoms assessed with the Zanarini Rating Scale for Borderline Personality Disorder. Secondary outcomes were functional impairment, quality of life, global functioning, and severe self-harm. All outcomes were primarily assessed at 16 months after randomization. This trial was prospectively registered at ClinicalTrials.gov, NCT03677037. Results Between October 4, 2018, and December 3, 2020, we randomly assigned 166 participants to short-term MBT (n=84) or long-term MBT (n=82). Regression analyses showed no evidence of a difference when assessing BPD symptoms (MD 0.99; 95% CI -1.06 to 3.03; p = 0.341), level of functioning (MD 1.44; 95% CI -1.43 to 4.32; p = 0.321), quality of life (MD -0.91; 95% CI -4.62 to 2.79; p = 0.626), global functioning (MD -2.25; 95% CI -6.70 to 2.20; p = 0.318), or severe self-harm (RR 1.37; 95% CI 0.70 to 2.84; p = 0.335). More participants in the long-term MBT group had a serious adverse event compared with short-term MBT (RR 1.63; 95% CI 0.94 to 3.07; p = 0.088) primarily driven by a difference in psychiatric hospitalizations (RR 2.03; 95% CI 0.99 to 5.09; p = 0.056). Conclusion Long-term MBT did not lead to lower levels of BPD symptoms, nor did it influence any of the secondary outcomes compared with short-term MBT.
DOI: 10.5517/ccdc.csd.cc2bb41w
title: CCDC 2154687: Experimental Crystal Structure Determination

description: Related Article: Athira C. Santhoshkumar, Basavaraja Durugappa, Siddalingeshwar V. Doddamani, Aiswarya Siby, Praveen K. Valmiki, Sasidhar B. Somappa|2023|Org.Lett.|25|7711|doi:10.1021/acs.orglett.3c03053
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d59qm
title: CCDC 2209640: Experimental Crystal Structure Determination

description: Related Article: Valerie A. Kuehl, Andrew M. Schmalzer, Christopher J. Snyder, David E. Chavez|2023|ACS Omega|8|38879|doi:10.1021/acsomega.3c02725
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f8s2l
title: CCDC 2242759: Experimental Crystal Structure Determination

description: Related Article: Qiao Ren, Ming Lang, Haitao Liu, Xiangyu Li, Daoshun Wu, Jiayun Wu, Meihua Yang, Jianhe Wei, Zhi Ren, Lei Wang|2023|Org.Lett.|25|7745|doi:10.1021/acs.orglett.3c03163
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f8s3m
title: CCDC 2242760: Experimental Crystal Structure Determination

description: Related Article: Qiao Ren, Ming Lang, Haitao Liu, Xiangyu Li, Daoshun Wu, Jiayun Wu, Meihua Yang, Jianhe Wei, Zhi Ren, Lei Wang|2023|Org.Lett.|25|7745|doi:10.1021/acs.orglett.3c03163
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f8s5p
title: CCDC 2242762: Experimental Crystal Structure Determination

description: Related Article: Qiao Ren, Ming Lang, Haitao Liu, Xiangyu Li, Daoshun Wu, Jiayun Wu, Meihua Yang, Jianhe Wei, Zhi Ren, Lei Wang|2023|Org.Lett.|25|7745|doi:10.1021/acs.orglett.3c03163
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2fpl5x
title: CCDC 2255069: Experimental Crystal Structure Determination

description: Related Article: Pan-Dong Mao, Hui-Ying Sun, Fei-Fei Yan, Shi-Hui Zhang, Xin-Feng Li, Ren-He Zhou, Yi-Quan Zhang, Yin-Shan Meng, Tao Liu|2023|CrystEngComm|25|6030|doi:10.1039/D3CE00720K
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.